Targets › TMPRSS6
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Sep 2028.
Membrane-bound serine protease. Through the cleavage of cell surface hemojuvelin (HJV), a regulator of the expression of the iron absorption-regulating hormone hepicidin/HAMP, plays a role in iron homeostasis. (UniProt, Q8IU80)
Open in Phaseline: the race on TMPRSS6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ono Pharmaceutical | Sapablursen (ONO-0530) Transmembrane protease serine 6 mRNA antisense inhibitor | TMPRSS6 | Phase 3 | Polycythemia Vera | Sep 2028 |
| Silence Therapeutics | SLN124 siRNA targeting TMPRSS6 mRNA | TMPRSS6 | Phase 1 | Polycythemia Vera | Mar 2030 |
Polycythemia Vera (2)
other (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.